[144] Incyte Genomics Inc SEC Filing

Rhea-AI Filing Summary

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) filed a Form 8-K dated July 14, 2025 reporting two material events.

• Item 2.02 – Results of Operations and Financial Condition: The Company released a preliminary estimate of its cash, cash equivalents and short-term investments as of June 30, 2025. No dollar amount was disclosed and management cautions that the figure is subject to change when full second-quarter results are issued.
• Item 8.01 – Other Events: A press release titled “Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)” was furnished as Exhibit 99.1 and incorporated by reference. Specific regulatory or business details are not included in the 8-K text.

The filing contains no detailed financial statements, earnings figures, or transactional information. Investors will need to review the forthcoming Form 10-Q and Exhibit 99.1 for quantitative data and substantive regulatory updates.

Insights

Financial Analyst

TL;DR: Neutral 8-K; only a preliminary cash snapshot and notice of Tab-cel regulatory update—no numbers, no guidance.

The filing serves mainly as a placeholder, signaling that management has sufficient visibility to reference its liquidity position and to highlight forthcoming regulatory news on Tabelecleucel. However, the absence of the actual cash figure or any qualitative insight into the regulatory pathway limits immediate valuation impact. Materiality will depend on the undisclosed cash balance and the substance of the press release in Exhibit 99.1, which is not included here. As presented, the disclosure is routine and informational without market-moving detail.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	14952	1023714.10	193569934	07/14/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/02/2025	Restricted Stock	ISSUER			3620	07/02/2025	Not Applicable
Common	07/02/2025	Performance Shares	ISSUER			11332	07/02/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What form did Atara Biotherapeutics (ATRA) file on July 14, 2025?

The company filed a Form 8-K current report with the U.S. Securities and Exchange Commission.

Which items are addressed in the ATRA Form 8-K?

The report covers Item 2.02 (preliminary cash estimate) and Item 8.01 (regulatory & business updates on Tabelecleucel).

Did Atara disclose its exact cash balance for June 30, 2025?

No. The 8-K states a preliminary cash, cash equivalents and short-term investments figure but does not provide the amount.

What exhibit accompanies the 8-K filing?

Exhibit 99.1 is a press release titled “Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®).”

Where is Atara Biotherapeutics’ stock listed and what is its ticker?

Atara’s common stock trades on The Nasdaq Stock Market LLC under the symbol ATRA.